Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

Dr. Miklos considers the possibility that ibrutinib could be used in combination with CAR T-cell therapies when treating aggressive relapsed/refractory lymphomas

Published: 14 December 2017

Recent Videos: ASH Conference Coverage

video

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)

video

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)

video

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

Dr. DeAngelo provides the mechanism of action of BLU-285 and explains what makes it unique and promising

video

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis

video

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward

video

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

Dr. Pui offers opinion on whether the FDA should accept minimal residual disease as a surrogate endpoint for regulatory approval

video

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

Dr. Pui describes how precision medicine is changing the way we treat pediatric acute lymphocytic leukemia (ALL) today

video

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

Dr. Pui tells us how he sees CAR T-cell therapy being used in pediatric acute lymphocytic leukemia (ALL) patients

video

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma ...

video

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

Dr. Cortes tells us about the clinical data presented at ASH 2017 regarding treatment of front-line chronic myelogenous leukemia (CML) ...

Related Videos

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

James R. Downing, MD, discusses the significant studies presented at ASH 2017

video-image

James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms

video-image

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

video-image

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

Paul Richardson, MD, on the importance of real world evidence (RWE)

video-image

Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients

video-image

Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms

video-image

Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD

video-image

Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD

video-image

Robert Soiffer, MD, discusses current treatments available for chronic GVHD

video-image

Robert Soiffer, MD, explains GVHD and some of the complications that come along with it

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms

video-image

Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing

video-image

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization

video-image

Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017

video-image

David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma

video-image

David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms

video-image

David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies

video-image

C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients

video-image

C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on the role social media plays in medicine

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies

video-image

Sagar Lonial MD, FACP, on expectations for response in the challenging patient type

video-image

Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens

video-image

Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients

video-image

Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab

video-image

Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective

video-image

Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate

video-image

Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies

video-image

Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade

video-image

Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations

video-image

Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML

video-image

Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling

video-image

Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy

video-image

Michael Kauffman, MD, on Selinexor regulatory and commercialization plans

video-image

Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016

video-image

Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016

video-image

David Miklos, MD, on developing an orphan drug for a small population of patients

video-image

Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016

video-image

Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin

video-image

Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients

video-image

C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients

video-image

C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients

video-image

C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why

video-image

C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative

video-image

Swaminathan Iyer, MD, discusses exciting new CLL treatment options

video-image

Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016

video-image

Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016

video-image

Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting

video-image

Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML

video-image

Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML

video-image

Alexander Perl, MD, discusses treatment options for AML patients

video-image

Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016

video-image

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

video-image

Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients

video-image

Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients

video-image

Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients

video-image

Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients

video-image

Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas

video-image

Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients

video-image

Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies

video-image

Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas

video-image

Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients

video-image

Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM

video-image

Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients

video-image

Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma

video-image

Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients

video-image

Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients

video-image

Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved

video-image

Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day

video-image

Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma

video-image

Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM

video-image

Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM

video-image

Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients

video-image

Michael Kauffman, MD, on how Selinexor works

video-image

Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies

video-image

Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies

video-image

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

video-image

Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016

video-image

Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD

video-image

Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients

video-image

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

video-image

Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development

video-image

Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients

video-image

Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients

video-image

Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT

video-image

Edward Copelan, MD, discusses the Levine Cancer Institute Program

video-image

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

video-image

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

video-image

Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL

video-image

Jane Winter, MD, talks about how personalized medicine is being applied to NHL

video-image

Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients

video-image

C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results

video-image

C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients

video-image

Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma

video-image

Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL

video-image

Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated

video-image

Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients

video-image

Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM

video-image

Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project

video-image

Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients

video-image

Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH

video-image

Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH

video-image

Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective

video-image

Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19

video-image

Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016

video-image

Susan O’Brien, MD, discusses CLL presentations at ASH 2016

video-image

Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma

video-image

Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016

video-image

Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data

video-image

Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML

video-image

Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016

video-image

Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)

video-image

Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today

video-image

Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015

video-image

ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab

video-image

Precision Medicine Coming to Bone Marrow Transplant

video-image

Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016

video-image

Advances In B-Cell Lymphoma From ASH 2015

video-image

Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL

video-image

Jeff Sharman, MD, offers perspective on CAR T-cell therapies for the treatment of NHL

video-image

Kathryn Kolibaba, MD, lists key takeaways from the lymphoma oral session at ASCO 2017

video-image

Kathryn Kolibaba, MD, shares the results of the MAGNIFY study presented at ASCO

video-image

Kathryn Kolibaba, MD, describes the results of the BRIGHT study in front-line indolent NHL patients